Many physiologic effects of l-glutamate, the major excitatory neurotransmitter in the
mammalian central nervous system, are mediated via signaling by ionotropic glutamate …

Treating major depression is a medical need that remains unmet by monoaminergic
therapeutic strategies that commonly fail to achieve symptom remission. A breakthrough in …

We show that the sex of human experimenters affects mouse behaviors and responses
following administration of the rapid-acting antidepressant ketamine and its bioactive …

Psychedelic drugs have reemerged as tools to treat several brain disorders. Cultural
attitudes toward them are changing, and scientists are once again investigating the neural …

Ketamine has rapid-onset antidepressant activity in patients with treatment-resistant major
depression (TRD). The safety and tolerability of racemic ketamine may be improved if given …

Nanomaterials have attractive physicochemical properties. A variety of nanomaterials such
as inorganic, lipid, polymers, and protein nanoparticles have been widely developed for …

Major depressive disorder (MDD) is a highly prevalent and disabling disorder. Despite the
many hypotheses proposed to understand the molecular pathophysiology of depression, it is …

While ketamine has been used clinically over the past decades, it has only been recently
shown to be a promising therapy for treatment-resistant depression (TRD). However …

Abstract (R, S)-ketamine (ketamine) and its enantiomer (S)-ketamine (esketamine) can
produce rapid and substantial antidepressant effects. However, individual response to …

Pain is the leading cause of medical consultations and occurs in 50–70% of emergency
department visits. To date, several drugs have been used to manage pain. The clinical use …